生命科学资讯
生物技术与制药领域的最新动态
Nuclear speckles enable processing of RNA from GC-rich isochores
Large-scale proteomics across neurological disorders uncovers biomarker panel and targets in multiple sclerosis
The MicrobeAtlas database: Global trends and insights into Earth’s microbial ecosystems
Vitamin B2 and B3 nutrigenomics reveals a therapy for NAXD disease
LUMI实验室:基于基础模型驱动的自主平台,助力发现用于mRNA递送的可离子化脂质设计方案
LUMI-lab: A foundation model-driven autonomous platform enabling discovery of ionizable lipid designs for mRNA delivery
编辑独脚金内酯激素受体以增强水稻抗病毒沉默能力
Editing strigolactone hormone receptor for robust antiviral silencing in rice
调控网络促进质外体碱化,启动感染部位远端组织的植物免疫。
A regulatory network promotes apoplastic alkalinization to prime plant immunity in tissues distal to site of infection
真菌来源的纤维二糖代谢途径助力T细胞绕过肿瘤内葡萄糖竞争
Fungal-derived cellobiose metabolic pathway fuels T cells to bypass intratumoral glucose competition
Vir公司因与Astellas的交易及“掩蔽”T细胞接合器研究结果股价上涨。
Vir climbs on Astellas deal, study results for ‘masked’ T cell engager
安斯泰来与Vir达成13亿美元CD3 T细胞衔接器交易。
Astellas and Vir in $1.3B deal for CD3 T-cell engager
Innovacell东京IPO募资9100万美元,用于资助尿失禁细胞疗法研发。
Innovacell’s $91M Tokyo IPO to fund incontinence cell therapies
加拉帕戈斯因细胞疗法业务缩减损失2.28亿欧元,但仍有资金进行交易活动。
Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking
单细胞多组学市场即将迎来繁荣 |• 10x Genomics • Illumina - openPR.com
Single Cell Multiomics Market Is Going to Boom |• 10x Genomics • Illumina - openPR.com
吉利德全面收购Arcellx。
Gilead brings Arcellx fully under the fold
吉利德以78亿美元收购Arcellx,押注多发性骨髓瘤细胞疗法。
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy
吉利德将以78亿美元收购细胞疗法合作伙伴Arcellx。
Gilead to acquire cell therapy partner Arcellx for $7.8B
细胞疗法过程表征全解析
All about cell therapy process characterization
溶酶体KICSTOR-GATOR1-SAMTOR营养感知超级复合物的结构
Structure of the lysosomal KICSTOR-GATOR1-SAMTOR nutrient-sensing supercomplex
生态困境中的共生固守
Symbiotic entrenchment through ecological Catch-22